Pricing Log in Create free account

AC Immune (ACIU) vs Greenwich LifeSciences, Inc. (GLSI)

AC Immune and Greenwich LifeSciences, Inc. are both Biotechnology companies. AC Immune and Greenwich LifeSciences, Inc. are of similar size ($227.0M and $222.7M). Greenwich LifeSciences, Inc. has the higher net margin (0.00% vs −962.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Greenwich LifeSciences, Inc. leads on 7 and AC Immune on 4.

Valuation

Metric ACIU GLSI Biotechnology median
P/E n/m n/m 10.60
P/S 21.29 n/m 9.40
P/B 4.52 71.16 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 9.06 n/m 9.02
Earnings yield (32.74%) (9.95%) (32.88%)
Free cash flow yield (55.75%) (5.63%) (23.13%)

Profitability

Metric ACIU GLSI Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (986.55%) 0.00% 0.00%
Net margin (962.17%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (122.01%) (986.31%) (51.96%)
Return on assets (33.75%) (374.46%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ACIU GLSI Biotechnology median
Revenue growth (TTM) (78.60%) — 6.76%
EPS growth (last fiscal year) (44.83%) (6.72%) 29.88%
Revenue growth, 5-year CAGR (47.84%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACIU GLSI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.85 1.54 4.97
Net debt to EBITDA 1.37 0.32 1.01

Dividend

Metric ACIU GLSI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACIU GLSI Biotechnology median
Market cap 226.96m 222.67m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack